Abstract:Abstract Selection of therapeutic targets and modalities is of fundamental importance in drug discovery, as it can have a direct impact on the economics of drug discovery as well as its success rate. With the advancement of chem-bio and proteomics methods together with advent of artificial intelligence, the scope of the druggable proteome is expanding. The choice of drug targets gains further importance as we link it to potential clinical efficacy and safety, genetic variation and patient populations. Drug targets are often selected based on inadequate understanding of target biology, tractability by existing toolbox of therapeutic modalities and insufficient insight into possible clinical outcome. We have developed an “Atlas of Therapeutic Targets”, an interactive resource that provides classification of drug target families with linked information on clinical and investigational drugs. The atlas also provides key insights and score for tractability of targets with various therapeutic modalities. Particularly, our scoring system grades the targets on dimensions such as ligandability, involvement in protein-protein complexes, structural disorder, hotspot analysis and cross-referencing with known targets, thus yielding a total tractability score of 1-10. Dissection of targets based on such dimensions, enables critical evaluation therapeutic modalities as well tools and methodologies needed for their conversion into successful drug discovery programs. We curate 900+ human drug targets, analysis of which indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms. This atlas will be available as a resource for the wide drug discovery community. Citation Format: Ivan Babic, Elmar Nurmemmedov. Atlas of therapeutic targets: Evolution of druggable proteome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3545.

Evolutionary Survey Of Druggable Protein Targets With Respect To Their Subcellular Localizations

Learning the Drug Target-Likeness of A Protein

Does Drug-Target Have A Likeness?

Evolutionary And Genetic Features Of Drug Targets

Sequence-Derived Markers Of Drug Targets And Potentially Druggable Human Proteins

Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs

The drug target genes show higher evolutionary conservation than non-target genes.

Can Medical Genetics and Evolutionary Biology Inspire Drug Target Identification?

Evolution of drug-binding residues in eukaryotic ribosomes

GETdb: a comprehensive database for genetic and evolutionary features of drug targets

A Survey On The Computational Approaches To Identify Drug Targets In The Postgenomic Era

Therapeutic targets: Progress of their exploration and investigation of their characteristics (vol 58, pg 259, 2006)

Unexplored Therapeutic Opportunities in the Human Genome

DrugDomain: the evolutionary context of drugs and small molecules bound to domains

Analysis of protein features and machine learning algorithms for prediction of druggable proteins

Abstract 3545: Atlas of therapeutic targets: Evolution of druggable proteome

Network-Based Relating Pharmacological and Genomic Spaces for Drug Target Identification

DrugProtAI: A guide to the future research of investigational target proteins

Exploiting Chemical Probes for Identifying Drug Target Proteins

A Review of Recent Advances and Research on Drug Target Identification Methods.

Target Discovery and Validation in the Post-Genomic Era